Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Tesla Yudhistira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacology, College of Pharmacy; Center for RNA Nanotechnology and Nanomedicine; James Comprehensive Cancer Center, C…. Hauptthemen laut MEDLINE: Liver Neoplasms, Drug Resistance, Neoplasm, Carcinoma, Hepatocellular, ATP-Binding Cassette Transporters. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 331 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NIGMS NIH HHS, National Institute of Biomedical Imaging and Bioengineering.
Abstract (Originalsprache)
Liver cancer, particularly hepatocellular carcinoma (HCC), poses significant treatment challenges due to chemoresistance and cancer recurrence. Similar to customs at the border, the liver detoxifies incoming chemicals via efflux pumps and overexpresses ATP-binding cassette (ABC) drug exporters, leading to chemoresistance. ABC contains a multihomosubunit structure and a revolving transport mechanism, actively effluxing drugs from cancer cells, thereby reducing intracellular drug accumulation and therapeutic efficacy. Based on the understanding of the dsDNA translocating mechanism and complete inhibition observed in the multihomosubunit-revolving ATPase of the Phi29 DNA packaging motor, we report here an unprecedented approach to develop a potent HCC drug mimicking the series-circuits of "Christmas light bulbs", as described by the calculation formula: x=(p+q)z=∑M=0Z(ZM)pZ-MqM=∑M=0Z(Z!M!(Z-M)!)pZ-MqM. RNA nanotechnology offers a novel "Christmas light bulb series circuit" strategy, inspired by the Phi29 hexameric RNA-driven DNA packaging motor, in which targeting a single subunit completely inhibits the entire cassette. The concept has been validated by delivering Paclitaxel and miRNA via RNA nanostructures to inhibit the homomeric multisubunit ABC drug efflux pump P-gp in HCC in a mouse model. The programmable and multivalent nature of RNA nanotechnology enables the codelivery of multiple high-payload therapeutics, combined with liver-targeting ligands such as GalNAc, thereby achieving synergistic anticancer effects. This review highlights the mechanistic insights into potent HCC drug design, the advantages of RNA nanotechnology, and the structure-function relationship of ABC and other ATPase transporters, emphasizing a targeted strategy to overcome chemoresistance in liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutics and Pharmacology, College of Pharmacy; Center for RNA Nanotechnology and Nanomedicine; James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, U…
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City 406040, Taiwan.
- Department of Medicine, The MetroHealth System, Case Western Reserve University, 2500 Metro Health Drive, Cleveland, Ohio 44109, United States.
ORCID-Profile: Bennett Yunker, Laksh Dhir, Peixuan Guo
Förderung
- NEI NIH HHS
- NIGMS NIH HHS
- National Institute of Biomedical Imaging and Bioengineering
- Ohio State University
- National Institute of General Medical Sciences
Zitieren
APA
Yudhistira, T., Yunker, B., Dhir, L., Ho, Y. S., Liu, S., & Guo, P. (2026). Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01025
Vancouver
Yudhistira T, Yunker B, Dhir L, Ho YS, Liu S, Guo P. Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01025
BibTeX
@article{Yudhistira2026,
author = {Yudhistira, Tesla and Yunker, Bennett and Dhir, Laksh and Ho, Yuan-Soon and Liu, Shujun and Guo, Peixuan},
title = {Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01025}
}
EUVIMED